An observational study in Neonates or Premature Babies, Patient With Urinary Catheter and Patient Hospitalized in NICU, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Bernard L, Bouattour Y, Masse M, Boeuf B, Decaudin B, Genay S, Lambert C, Moreau E, Pereira B, Pinguet J, Richard D, Sautou V, For The Armed Study Group. Assoc…PubMed 33921860 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.
Among the 205 studies in Premature Birth with a site in France, this one is the 54th largest by enrollment of the 99 observational ones that give a count, is one of 19 that started in 2018, is one of 99 observational ones, and was the 86th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 5 mo · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 0 mo–18 mo
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6 yrs–78 mo
Bioprojet · Sites in France
Ages 18–50 · Men only
Hospices Civils de Lyon · Sites in France
Ages up to 32 wk
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 1 Day to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 12 · Phase 4 10
First in 1997; this study’s year is marked. 19 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is below the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 98 across the 104 interventional studies, 130 across the 99 observational. Of the 139 that completed or were terminated, 2 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 205 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 7 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
16 of the studies in Premature Birth with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976063Phase 3Assistance Publique - Hôpitaux de ParisTocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06064825Institut National de la Santé Et de la Recherche Médicale, FranceLong Term Follow-up of the TREOCAPA Study (TREOCAPA-LT) | 2026-12 |
| NCT07047404BioprojetProof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation | 2026-12 |
| NCT07169110University Hospital, ToulouseStudy of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants | 2026-12-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 205 studies in Premature Birth with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In response to restrictions related to the use of DEHP as a plasticizer for PVC medical devices (MDs), manufacturers have resorted to alternative plasticizers. These are now integrated into many MDs such as infusion sets, extension lines, extracorporeal circuits, nutrition tubings ... etc. The ARMED project (2012-2015) funded by the ANSM, whose goal was to prioritizing the risk linked to the migration of these plasticizers from MDs, has shown that TOTM and DEHT present the best benefit / risk ratio due to lower migration and cytotoxicity. Nevertheless, it is important to evaluate the level of exposure of neonatal intensive care patients, due to the multi exposure to MD made of PVC, the frequent use of intravenous route and the vulnerability of this at-risk population to the metabolites of these plasticizers.
The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
minor patient in NICU
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
Other: plasticizers
The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
Measurement of urinary levels of DEHT metabolites
The studied metabolites are specific biological markers
Time frame: at day 1
Measurement of urinary levels of TOTM metabolites
The studied metabolites are specific biological markers
Time frame: at day 1
Correlation of urinary levels of TOTM and DEHT metabolites to corresponding plasticizers doses released by PVC medical devices to which patients are exposed
Quantities of plasticizers (TOTM and DEHT) are measured within each MD to which neonates are exposed in NICU. The release doses of plasticizers are evaluated with mathematical model (built from ex vivo experimentations). The study evaluates whether there is a correlation between the doses of TOTM and the DEHT released by the MD and the metabolites levels found in the urine of exposed patients
Time frame: 18 months after the beginning of the study
Comparison of urinary levels of TOTM and DEHT and their metabolites to in vitro cytotoxicity and endocrine disruption and to toxicological data from the literature.
The Armed Neo project include laboratory studies to evaluate the cytotoxicity and endocrine disrupting effects of plasticizers and their metabolites. These studies show the concentrations above which DHT, TOTM and metabolites are toxic. The concentrations obtained in the urines of newborns will be compared to these toxicity threshold values
Time frame: 18 months after the beginning of the study
Ran from Feb 2018 to primary completion in Nov 2018, 9 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jan 2019 → Nov 2018 and completion Jan 2019 → Apr 2019.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Bernard L, Bouattour Y, Masse M, Boeuf B, Decaudin B, Genay S, Lambert C, Moreau E, Pereira B, Pinguet J, Richard D, Sautou V, For The Armed Study Group. Assoc…PubMed 33921860 ↗
Bernard L, Bouattour Y, Masse M, Boeuf B, Decaudin B, Genay S, Lambert C, Moreau E, Pereira B, Pinguet J, Richard D, Sautou V, For The Armed Study Group. Assoc…PubMed 33921860 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →